Pricing database updated August 4, 2026Methodology v1.0How we score →
Compare Providers
Home / GLP-1 / GLP-1 medications and menopause
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Written by Dr. Parmis Mojarab, DO·Reviewed by Kim Callender, NP, FNP-BC·Published July 12, 2026·Last reviewed August 4, 2026·Methodology v1.0
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.

GLP-1 medications and menopause

Quick answer

Menopause is associated with metabolic shifts and weight gain, and GLP-1 medications are increasingly used in this population. They are not menopause treatments; they address weight and glycemic control, and eligibility and safety are individual clinical questions.

Why interest is rising

Hormonal changes around menopause can shift fat distribution and make weight harder to manage. GLP-1 agents target appetite and metabolism, which is why interest has grown — but they treat weight, not menopause itself.

What to consider

Bone and muscle health matter more with age; muscle-preserving strategies (protein, resistance training) pair with GLP-1 therapy. Discuss individual risks with a clinician.

Frequently asked questions

Can GLP-1 medications help with menopause weight gain?

They can support weight management in this population, but they are not menopause therapies and eligibility is an individual clinical decision.

Sources

  1. U.S. Food and Drug Administration — labels and safety communications.
  2. Peer-reviewed clinical trials cited above.
  3. Our methodology and medical review policy.

Spotted an error? Submit a correction.

How the dates on this page work. Manufacturer self-pay prices — NovoCare and LillyDirect — were re-read on the manufacturers’ own published price guides on 4 August 2026. Figures captured from third-party provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row says so. We do not restamp a figure we have not re-read.